| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Sukhatme Mayukh | President & CIO, Director | C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM | By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme | 19 Dec 2025 | 0001750050 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ROIV | Common Shares | Options Exercise | $754,625 | +59,513 | +0.32% | $12.68 | 18,896,060 | 17 Dec 2025 | Direct | |
| transaction | ROIV | Common Shares | Sale | $619,528 | -26,831 | -0.14% | $23.09 | 18,869,229 | 17 Dec 2025 | Direct | F1 |
| transaction | ROIV | Common Shares | Other | $754,627 | -32,682 | -0.17% | $23.09 | 18,836,547 | 17 Dec 2025 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ROIV | Common Shares | Options Exercise | $0 | -59,513 | -4.4% | $0.000000 | 1,304,198 | 17 Dec 2025 | Common Shares | 59,513 | $12.68 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
| F2 | Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. |
| F3 | Award of stock options to purchase Common Shares that is fully vested. |